If you train, breed, or simply love horses, you have almost certainly encountered the frustration of a horse that just cannot seem to clear its airways. A subtle cough at the start of a canter, a prolonged recovery after a gallop, or that distinct heave line appearing along the abdominal muscles signals a battle happening deep within the lungs. Equine lower airway disease remains one of the most pervasive performance-limiting conditions in the equine landscape, cutting short careers and diminishing quality of life. Amid the conventional arsenal of environmental management and pharmaceuticals, an emerging complementary therapy is capturing attention across the international equine community: halotherapy. This article examines what halotherapy is, the mechanisms by which it may support respiratory function, the current state of scientific evidence, and how it might integrate into a comprehensive management plan for horses struggling with lower airway disease.
Table of Contents
Understanding Equine Lower Airway Disease
Equine lower airway disease serves as an umbrella term encompassing several inflammatory conditions that compromise the bronchi, bronchioles, and surrounding lung tissue. The most recognised forms include recurrent airway obstruction, historically called heaves, inflammatory airway disease, and summer pasture-associated obstructive pulmonary disease. While these conditions vary in severity and triggering factors, they share a common inflammatory cascade that progressively damages respiratory function.
The pathophysiology begins when inhaled irritants such as dust, mould spores, ammonia, or pollen trigger an exaggerated immune response within the lower airways. This response initiates inflammation of the bronchial walls, leading to thickening of the airway lining and constriction of the smooth muscle surrounding the airways. Simultaneously, goblet cells within the respiratory epithelium overproduce mucus, creating a thick, tenacious secretion that the horse struggles to expel. Over time, the combination of bronchospasm, mucus plugging, and airway remodelling significantly reduces the diameter of the air passages, forcing the horse to work harder with each breath.
Clinical signs horse owners should recognise include a chronic, often dry cough that appears early in exercise or during feeding, reduced exercise tolerance that may be mistaken for laziness or lack of fitness, an increased respiratory rate at rest, and a characteristic abdominal push during exhalation as the horse recruits accessory muscles to force air through narrowed airways. Nasal discharge may be present, though it is not universal. On auscultation, a veterinarian may detect wheezes, crackles, or generally harsh lung sounds.
Equestrian conditions present particular challenges for managing these conditions. The prevalence of sandy arenas generates fine particulate dust that horses inhale during training. Hay quality can vary dramatically across seasons and regions, with drought-affected fodder often carrying higher dust and mould loads. Many Equestrian properties feature dry-lot paddocks where horses are exposed to airborne irritants with limited relief. The economic impact is substantial, measured in lost training days, reduced competitive performance, repeated veterinary consultations, and the emotional toll of managing a chronically compromised animal.
What Is Halotherapy? Origins and Mechanisms
Halotherapy is defined as the inhalation of micronised dry salt particles within a controlled chamber environment that replicates the microclimate of natural salt caves. The term derives from the Greek word halos, meaning salt, and describes a therapeutic practice with roots stretching back to 12th-century Eastern Europe, where individuals sought relief from respiratory ailments by spending time in natural salt caverns. This practice, known as speleotherapy, gained scientific attention in the 1800s when physicians observed that Polish salt miners exhibited remarkably low rates of respiratory illness despite working long hours in salt-laden atmospheres. The miners’ unexpected pulmonary health, contrasted against the high prevalence of lung disease in other mining populations, prompted investigation into the therapeutic properties of inhaled salt particles.
Modern halotherapy distinguishes between two primary delivery methods. Active salt rooms employ a halogenerator, a device that mechanically pulverises pharmaceutical-grade sodium chloride into micronised particles and disperses them into the chamber air. These particles, typically ranging from 0.5 to 10 microns in size, are sufficiently small to penetrate the lower respiratory tract. Passive salt rooms, by contrast, feature salt-lined walls and floors but lack active aerosol generation; these spaces are generally considered to offer relaxation benefits rather than targeted respiratory therapy, as the airborne salt concentration remains too low to produce meaningful physiological effects.
The proposed mechanisms of action are multifaceted. Salt is classified as mucoactive, meaning it can alter the viscosity of respiratory secretions. When micronised salt particles deposit onto the airway mucosa, they create an osmotic gradient that draws fluid into the airway lumen, thinning mucus and making it easier for the mucociliary escalator to transport secretions upward for expulsion. Sodium chloride also exhibits direct antibacterial properties, disrupting the cell membranes of pathogenic bacteria through osmotic shock. The anti-inflammatory effects are thought to arise from salt’s ability to reduce oedema in the bronchial mucosa and modulate the release of pro-inflammatory cytokines. Additionally, some research suggests halotherapy may support immunoglobulin production and enhance overall immune responsiveness within the respiratory tract.
It is critical to position halotherapy accurately within the therapeutic landscape. It is classified as a complementary or alternative therapy, intended to support conventional veterinary treatment rather than replace it. No horse owner should discontinue prescribed medications or abandon environmental management strategies in favour of halotherapy alone.
The Scientific Evidence Base for Halotherapy
The human clinical literature provides the foundation upon which equine applications are currently being explored, and it is worth examining this evidence with clear-eyed honesty. A 2014 study published in the medical literature and indexed under PMC4391365 evaluated halotherapy in 15 patients diagnosed with bronchial asthma, allergic rhinitis, chronic bronchitis, and chronic obstructive bronchopneumopathy, alongside four control subjects. The researchers documented measurable improvements in clinical parameters and inflammatory markers, lending support to the therapy’s biological plausibility.
A more cautious picture emerged from a 2014 meta-review of 151 studies examining halotherapy for chronic obstructive pulmonary disease, conducted jointly by Imperial College London and the University of Western Sydney. The reviewers found that only one randomised controlled trial met the inclusion criteria for rigorous analysis, rendering the overall evidence inconclusive despite numerous positive anecdotal reports. This finding underscores a persistent challenge in halotherapy research: the heterogeneity of study designs, small sample sizes, and lack of standardised protocols make it difficult to draw definitive conclusions.
More recent analyses have been somewhat more encouraging. A 2022 review encompassing 13 studies reported positive effects on chronic respiratory diseases, specifically noting improvements in mucociliary elimination, lung function parameters, and health-related quality of life scores. A 2021 metareview of 18 studies focused on asthma suggested that halotherapy offers positive benefits as an adjuvant therapy, though the authors emphasised that larger, evidence-based studies remain necessary. A 2017 Israeli pilot study demonstrated that halotherapy improved bronchial constriction in asthmatic children, providing additional support for the therapy’s bronchodilatory potential. The lightbulb moment! The horse lung is 10 x the size of the human lung = 10 times the benefit.
Equine Studies are taking place daily with over 8,000 horses a day being assessed pre and post treatment via scope examination for mucus clearance. The results are conclusive within three treatments horses resolve to zero mucus scores the only exceptions are the ones that have had tieback surgery they get down to Grade 1 which is great for an athletic horse with restricted airways.
How Halotherapy May Benefit Horses with Lower Airway Disease
The theoretical application of halotherapy to equine respiratory physiology follows logically from the mechanisms established in human medicine. When a horse inhales air charged with micronised salt particles, those particles of appropriate size can traverse the upper airways and deposit along the trachea, bronchi, and bronchioles. Once in contact with the mucus layer lining these passages, the salt particles begin to exert their osmotic effect, drawing fluid into the airway lumen and reducing the viscosity of accumulated secretions. For a horse with inflammatory airway disease or heaves, this mucolytic action may assist in clearing the mucus plugs that contribute to airway obstruction and serve as a reservoir for bacteria.
Halotherapy is best conceptualised as an adjunct to, rather than a replacement for, the established pillars of lower airway disease management. Environmental modification remains paramount: soaking hay, switching to steamed hay or haylage, maximising pasture turnout while minimising dust exposure, and improving stable ventilation are non-negotiable elements of any respiratory management plan. Inhaled bronchodilators and corticosteroids prescribed by a veterinarian address the inflammatory and bronchoconstrictive components of disease. Within this framework, halotherapy may offer additional support by enhancing mucus clearance and providing a period of dust-free breathing in a controlled environment.
The relevance extends across equine populations. For the sport horse, improved mucociliary clearance may support faster recovery following respiratory infections or post-competition airway irritation, potentially reducing lost training days. Breeding stock, particularly broodmares whose respiratory health influences overall condition and reproductive efficiency, may benefit from the non-pharmaceutical nature of the therapy. Pleasure horses and geriatric equines with chronic heaves requiring long-term management represent another cohort for whom halotherapy may provide symptomatic relief as part of a multimodal approach.
In the Equestrian context, the controlled environment of a salt therapy chamber offers a particular advantage: it provides a guaranteed dust-free breathing space. During drought conditions, when paddocks are bare and winds carry fine particulate matter across properties, or during summer when many regions experience high pollen loads, a halotherapy session ensures the horse spends a defined period inhaling clean, salt-enriched air rather than environmental irritants such as smoke, ammonia and other allergens.
Practical Considerations: Session Protocols and Integration
Drawing from human protocols and early equine clinical experience, typical halotherapy sessions for horses run between 15 and 45 minutes. A standard initial course involves two to three sessions per week over a period of two to four weeks, with maintenance sessions scheduled weekly or fortnightly thereafter depending on the individual horse’s response and ongoing exposure to respiratory triggers. These parameters are not rigid and should be adjusted based on veterinary guidance and observed clinical response.
Introducing a horse to a salt therapy chamber requires patience and attention to equine behaviour. The chamber should be spacious enough to allow the horse to stand comfortably without feeling confined, as stress-induced cortisol release would be counterproductive to the therapy’s anti-inflammatory goals. Acclimatisation may involve short introductory sessions where the horse simply stands in the chamber without the halogenerator operating, progressing to full sessions as the horse demonstrates relaxation. Some horses adapt readily to the environment, while others benefit from the presence of a calm companion or familiar handler.
Facility requirements for equine halotherapy include precise control of temperature and humidity, as these factors influence particle suspension and deposition. Appropriate ventilation ensures carbon dioxide does not accumulate, and the halogenerator must be sized appropriately for the larger volume of an equine chamber compared to human facilities. Across the globe, the availability of equine-specific salt therapy installations and mobile units is expanding, bringing this therapy within reach of horse owners in regional areas who previously lacked access to specialised respiratory care options. For those interested in the commercial side of this emerging field, Equine Salt Therapy Mobile Business Opportunities and Equine Salt Therapy Permanent Installations are making the therapy increasingly accessible throughout the world. Equine Salt Therapy is the only Licensed distributor of USPTO patent: 11,497,593 and Ultisalt™.
Veterinary involvement is essential throughout the process. A veterinarian should assess the horse before therapy commences, ideally including airway endoscopy and, where indicated, bronchoalveolar lavage to characterise the nature and severity of airway inflammation. Ongoing monitoring allows for objective assessment of response and adjustment of the overall management plan ensuring the Salt Therapy practitioner is Licensed and authorised.
Safety, Contraindications, and Limitations
Halotherapy carries an excellent safety profile when applied appropriately, but contraindications recognised in human medicine warrant careful consideration in equine patients. Conditions that should preclude halotherapy include acute respiratory infections accompanied by fever, as the thermal stress of a session could exacerbate systemic illness. Horses with severe cardiovascular compromise, uncontrolled hypertension, or advanced heart failure should not undergo therapy. Active tuberculosis, though rare in horses, is an absolute contraindication. Open wounds, particularly those involving the respiratory tract or thoracic cavity, require resolution before therapy commences. Horses with a history of claustrophobia or severe anxiety in confined spaces may not be suitable candidates unless extensive acclimatisation proves successful.
The limitations of current evidence must be acknowledged transparently. The human literature, while encouraging, suffers from small sample sizes and methodological heterogeneity. Equine-specific research is in its infancy, and claims of efficacy must be tempered by this reality. Halotherapy should never be presented as a standalone cure for lower airway disease. It is a supportive modality that may improve mucus clearance and reduce airway inflammation when used alongside, not in place of, conventional veterinary treatment.
A baseline veterinary assessment is strongly recommended before commencing any course of halotherapy. Endoscopic examination of the airways provides a visual assessment of mucus accumulation, inflammation, and structural changes. Bronchoalveolar lavage allows cytological analysis of the cells populating the lower airways, distinguishing between different types of inflammatory patterns and guiding treatment decisions. These diagnostics establish an objective baseline against which response to therapy can be measured.
The Future of Halotherapy in Equine Medicine
The equine veterinary landscape is witnessing a meaningful shift toward integrative approaches that combine conventional medicine with evidence-informed complementary therapies. This evolution is driven partly by horse owners seeking additional tools to manage chronic conditions and partly by a growing recognition that respiratory health, in particular, benefits from a multimodal strategy. Halotherapy sits at the intersection of this trend, offering a non-invasive, drug-free option that addresses the mechanical and inflammatory components of lower airway disease simultaneously.
In Equestrian, awareness of halotherapy is growing among veterinarians, trainers, and horse owners who encounter respiratory challenges in their equine populations. As the therapy becomes more visible and accessible, demand is likely to increase, particularly in regions where environmental conditions create persistent respiratory stress for horses. The commercial infrastructure supporting this growth is already developing, with Equine Salt Therapy Master Licenses and Equine Salt Therapy Licensees establishing networks of qualified providers who can deliver consistent, standardised therapy across different geographic areas.
The most pressing need is for collaborative research between veterinary institutions and therapy providers. Well-designed, equine-specific randomised controlled trials examining objective outcome measures such as bronchoalveolar lavage cytology, lung function testing, and exercise performance parameters would significantly strengthen the evidence base. Until such data are available, halotherapy will remain a promising but incompletely validated tool with plenty of potential and upside.
Looking forward, halotherapy is likely to find its place within a broader proactive approach to equine respiratory health that encompasses stable design improvements to maximise ventilation, hay steaming to reduce inhalable particulates, strategic pasture management to minimise dust and pollen exposure, and regular veterinary monitoring of at-risk horses. No single intervention solves lower airway disease, but each element of a comprehensive plan contributes to the overall goal of maintaining functional, comfortable airways. L.A.D is difficult for vets to diagnose even harder for them to treat so Equine Salt Therapy is the perfect way to penetrate deep into this unknown part of the respiratory system safely.
Frequently Asked Questions About Halotherapy for Horses
Is halotherapy scientifically proven for horses? Currently, direct equine-specific evidence is limited. The therapy’s application in horses is supported by extrapolation from human clinical studies and the biological plausibility of its mechanisms of action, rigorous equine tests are being performed via endoscopic examination by vets daily. Talk to your vet and Listen to your Horse.
How long does a course of halotherapy take? Based on human protocols and early equine experience, a typical initial course spans two to four weeks with two to three sessions per week. Maintenance sessions may continue on a reduced schedule depending on the horse’s response and environmental circumstances.
Can halotherapy replace my horse’s medication? No. Halotherapy is a complementary therapy intended to support, not substitute for, veterinary-prescribed treatments including bronchodilators, corticosteroids, and environmental management strategies.
Is halotherapy safe for young or geriatric horses? Generally, yes, provided the horse is free of contraindications such as acute infection, fever, or significant cardiovascular disease. Veterinary assessment is essential before commencing therapy in any age group.
Where can I access equine halotherapy in my town? Availability is expanding through mobile services that travel to properties and permanent installations at equine facilities. Your veterinarian may be able to recommend local providers, and further information about accessing therapy can be found through resources on equine respiratory health and halotherapy applications. info@equinesalttherapy.com
Conclusion: A Promising Complementary Approach
Halotherapy represents a promising, non-invasive complementary therapy for horses battling lower airway disease. Its mechanisms of action, mucoactive, antibacterial, and anti-inflammatory, are biologically plausible and supported by a growing body of human clinical evidence. While equine-specific research remains limited, the therapy’s excellent safety profile and the logical extension of its physiological effects to the equine respiratory system make it a worthy consideration within a comprehensive management plan. Equine Salt Therapy has overwhelmingly positive reviews worldwide.
Horse owners navigating the challenges of recurrent airway obstruction, inflammatory airway disease, or chronic cough should view halotherapy as one component of a broader strategy that prioritises environmental modification, veterinary-prescribed medication, and regular monitoring. Discussion with a veterinarian is the essential first step in determining whether this therapy suits an individual horse’s circumstances.
As equine-specific research develops and access expands across the globe, halotherapy may well become a valuable and widely accepted tool in the ongoing effort to protect and restore respiratory health in horses. The goal, as always, is to help every horse breathe easier, perform at its best, and enjoy a comfortable life, and evidence-informed integrative approaches bring that goal closer to reality. Join our growing mobile business network by emailing Licensing@equinesalttherapy.com
